Needham, in a research note to investors on the biotech industry, mentioned Avidity (RNA) and Phathom Pharmaceuticals (PHAT) as the most likely takeout targets under coverage. The firm sees Regeneron (REGN), Bayer (BAYRY), and Novo Nordisk (NVO) as the most likely to buy earlier-stage companies, and Takeda (TAK), Biogen (BIIB), Bristol Myers (BMY), and Pfizer (PFE) as most likely to buy late-stage companies.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences Positioned for Leadership in Muscular Dystrophy with Strategic Regulatory Advancements
- Raymond James Predicts Up to ~760% Surge for These 2 ‘Strong Buy’ Stocks
- Avidity Biosciences price target raised to $70 from $60 at Evercore ISI
- Avidity Biosciences: Promising Advancements and Strategic Positioning Drive Buy Rating
- Avidity Biosciences resumed with a Buy at Goldman Sachs